Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
[P1]	 O
FOLFIRI	 O
[P2]	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
FOLFIRI	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
May	 O
29	 O
,	 O
2020	 O
May	 O
29	 O
,	 O
2020	 O
MDSotaroSadahiro	 O

Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
FOLFIRI	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
[P1]	 O
FOLFIRI	 O
[P2]	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
May	 O
29	 O
,	 O
2020	 O
May	 O
29	 O
,	 O
2020	 O
MDSotaroSadahiro	 O

Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
[P1]	 O
FOLFIRI	 O
[P2]	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O

Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
FOLFIRI	 O
plus	 O
[P1]	 O
Bevacizumab	 O
[P2]	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O

Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
[P1]	 O
Irinotecan	 O
[P2]	 O
plus	 O
Bevacizumab	 O
versus	 O
FOLFIRI	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
MDSotaroSadahiro	 O
sadahiro@is.icc.u-tokai.ac.jp	 O
Department	 O
of	 O
Surgery	 O
School	 O
of	 O
Medicine	 O
Tokai	 O
University	 O
Isehara	 O
Japan	 O
Department	 O
of	 O
Surgery	 O
School	 O
of	 O
Medicine	 O
Tokai	 O
University	 O

Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
[P1]	 O
Bevacizumab	 O
[P2]	 O
versus	 O
FOLFIRI	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
MDSotaroSadahiro	 O
sadahiro@is.icc.u-tokai.ac.jp	 O
Department	 O
of	 O
Surgery	 O
School	 O
of	 O
Medicine	 O
Tokai	 O
University	 O
Isehara	 O
Japan	 O
Department	 O
of	 O
Surgery	 O
School	 O
of	 O
Medicine	 O
Tokai	 O
University	 O

Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
[P1]	 O
FOLFIRI	 O
[P2]	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
MDSotaroSadahiro	 O
sadahiro@is.icc.u-tokai.ac.jp	 O
Department	 O
of	 O
Surgery	 O
School	 O
of	 O
Medicine	 O
Tokai	 O
University	 O
Isehara	 O
Japan	 O
Department	 O
of	 O
Surgery	 O
School	 O
of	 O
Medicine	 O
Tokai	 O
University	 O

Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
FOLFIRI	 O
plus	 O
[P1]	 O
Bevacizumab	 O
[P2]	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
MDSotaroSadahiro	 O
sadahiro@is.icc.u-tokai.ac.jp	 O
Department	 O
of	 O
Surgery	 O
School	 O
of	 O
Medicine	 O
Tokai	 O
University	 O
Isehara	 O
Japan	 O
Department	 O
of	 O
Surgery	 O
School	 O
of	 O
Medicine	 O
Tokai	 O
University	 O

Japan	 O
Isehara	 O
Japan	 O
Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
[P1]	 O
Bevacizumab	 O
[P2]	 O
versus	 O
FOLFIRI	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
May	 O
29	 O
,	 O
2020	 O
May	 O
29	 O
,	 O
2020	 O
May	 O
29	 O
,	 O
2020	 O
10.1159/000507293	 O
Received	 O
:	 O
February	 O
18	 O
,	 O
2020	 O
Accepted	 O
:	 O
March	 O
16	 O
,	 O
2020	 O

Japan	 O
Isehara	 O
Japan	 O
Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
[P1]	 O
FOLFIRI	 O
[P2]	 O
plus	 O
Bevacizumab	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
May	 O
29	 O
,	 O
2020	 O
May	 O
29	 O
,	 O
2020	 O
May	 O
29	 O
,	 O
2020	 O
10.1159/000507293	 O
Received	 O
:	 O
February	 O
18	 O
,	 O
2020	 O
Accepted	 O
:	 O
March	 O
16	 O
,	 O
2020	 O

Japan	 O
Isehara	 O
Japan	 O
Oral	 O
S-1	 O
with	 O
24-h	 O
Infusion	 O
of	 O
Irinotecan	 O
plus	 O
Bevacizumab	 O
versus	 O
FOLFIRI	 O
plus	 O
[P1]	 O
Bevacizumab	 O
[P2]	 O
as	 O
First	 O
-	 O
Line	 O
Chemotherapy	 O
for	 O
Metastatic	 O
Colorectal	 O
Cancer	 O
:	 O
An	 O
Open	 O
-	 O
Label	 O
Randomized	 O
Phase	 O
II	 O
Trial	 O
May	 O
29	 O
,	 O
2020	 O
May	 O
29	 O
,	 O
2020	 O
May	 O
29	 O
,	 O
2020	 O
10.1159/000507293	 O
Received	 O
:	 O
February	 O
18	 O
,	 O
2020	 O
Accepted	 O
:	 O
March	 O
16	 O
,	 O
2020	 O

In	 O
this	 O
open	 O
-	 O
label	 O
randomized	 O
phase	 O
II	 O
trial	 O
,	 O
we	 O
compared	 O
combination	 O
treatment	 O
consisting	 O
of	 O
oral	 O
S-1	 O
and	 O
a	 O
24-h	 O
infusion	 O
of	 O
irinotecan	 O
plus	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
with	 O
conventional	 O
FOLFIRI	 O
plus	 O
bevacizumab	 O
as	 O
first	 O
-	 O
line	 O
chemotherapy	 O
for	 O
mCRC	 O
.	 O

In	 O
this	 O
open	 O
-	 O
label	 O
randomized	 O
phase	 O
II	 O
trial	 O
,	 O
we	 O
compared	 O
combination	 O
treatment	 O
consisting	 O
of	 O
oral	 O
S-1	 O
and	 O
a	 O
24-h	 O
infusion	 O
of	 O
irinotecan	 O
plus	 O
bevacizumab	 O
with	 O
conventional	 O
[P1]	 O
FOLFIRI	 O
[P2]	 O
plus	 O
bevacizumab	 O
as	 O
first	 O
-	 O
line	 O
chemotherapy	 O
for	 O
mCRC	 O
.	 O

In	 O
this	 O
open	 O
-	 O
label	 O
randomized	 O
phase	 O
II	 O
trial	 O
,	 O
we	 O
compared	 O
combination	 O
treatment	 O
consisting	 O
of	 O
oral	 O
S-1	 O
and	 O
a	 O
24-h	 O
infusion	 O
of	 O
irinotecan	 O
plus	 O
bevacizumab	 O
with	 O
conventional	 O
FOLFIRI	 O
plus	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
as	 O
first	 O
-	 O
line	 O
chemotherapy	 O
for	 O
mCRC	 O
.	 O

Patients	 O
were	 O
randomly	 O
assigned	 O
in	 O
a	 O
1:1	 O
ratio	 O
to	 O
receive	 O
oral	 O
S-1	 O
with	 O
a	 O
24-h	 O
infusion	 O
of	 O
irinotecan	 O
plus	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
(	 O
24h	 O
-	 O
SIRI	 O
/	 O
B	 O
)	 O
or	 O
FOLFIRI	 O
plus	 O
bevacizumab	 O
(	 O
FOLFIRI	 O
/	 O
B	 O
)	 O
.	 O

Patients	 O
were	 O
randomly	 O
assigned	 O
in	 O
a	 O
1:1	 O
ratio	 O
to	 O
receive	 O
oral	 O
S-1	 O
with	 O
a	 O
24-h	 O
infusion	 O
of	 O
irinotecan	 O
plus	 O
bevacizumab	 O
(	 O
24h	 O
-	 O
[P1]	 O
SIRI	 O
/	 O
B	 O
[P2]	 O
)	 O
or	 O
FOLFIRI	 O
plus	 O
bevacizumab	 O
(	 O
FOLFIRI	 O
/	 O
B	 O
)	 O
.	 O

Patients	 O
were	 O
randomly	 O
assigned	 O
in	 O
a	 O
1:1	 O
ratio	 O
to	 O
receive	 O
oral	 O
S-1	 O
with	 O
a	 O
24-h	 O
infusion	 O
of	 O
irinotecan	 O
plus	 O
bevacizumab	 O
(	 O
24h	 O
-	 O
SIRI	 O
/	 O
B	 O
)	 O
or	 O
[P1]	 O
FOLFIRI	 O
[P2]	 O
plus	 O
bevacizumab	 O
(	 O
FOLFIRI	 O
/	 O
B	 O
)	 O
.	 O

Patients	 O
were	 O
randomly	 O
assigned	 O
in	 O
a	 O
1:1	 O
ratio	 O
to	 O
receive	 O
oral	 O
S-1	 O
with	 O
a	 O
24-h	 O
infusion	 O
of	 O
irinotecan	 O
plus	 O
bevacizumab	 O
(	 O
24h	 O
-	 O
SIRI	 O
/	 O
B	 O
)	 O
or	 O
FOLFIRI	 O
plus	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
(	 O
FOLFIRI	 O
/	 O
B	 O
)	 O
.	 O

Patients	 O
were	 O
randomly	 O
assigned	 O
in	 O
a	 O
1:1	 O
ratio	 O
to	 O
receive	 O
oral	 O
S-1	 O
with	 O
a	 O
24-h	 O
infusion	 O
of	 O
irinotecan	 O
plus	 O
bevacizumab	 O
(	 O
24h	 O
-	 O
SIRI	 O
/	 O
B	 O
)	 O
or	 O
FOLFIRI	 O
plus	 O
bevacizumab	 O
(	 O
[P1]	 O
FOLFIRI	 O
/	 O
B	 O
[P2]	 O
)	 O
.	 O

The	 O
24h	 O
-	 O
[P1]	 O
SIRI	 O
/	 O
B	 O
[P2]	 O
regimen	 O
comprised	 O
irinotecan	 O
(	 O
125	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
a	 O
24-h	 B-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
on	 I-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
15	 I-DOSAGE
,	 O
S-1	 O
(	 O
80	 B-DOSAGE
mg/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 B-DOSAGE
orally	 I-DOSAGE
in	 I-DOSAGE
two	 I-DOSAGE
divided	 I-DOSAGE
daily	 I-DOSAGE
doses	 I-DOSAGE
on	 I-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
-	 I-DOSAGE
14	 I-DOSAGE
,	 O
and	 O
bevacizumab	 O
(	 O
5.0	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
an	 O
intravenous	 O
infusion	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
15	 I-DOSAGE
of	 I-DOSAGE
each	 I-DOSAGE
4-week	 I-DOSAGE
cycle	 I-DOSAGE
.	 O

The	 O
24h	 O
-	 O
SIRI	 O
/	 O
B	 O
regimen	 O
comprised	 O
irinotecan	 O
(	 O
125	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
a	 O
24-h	 B-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
on	 I-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
15	 I-DOSAGE
,	 O
S-1	 O
(	 O
80	 B-DOSAGE
mg/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 B-DOSAGE
orally	 I-DOSAGE
in	 I-DOSAGE
two	 I-DOSAGE
divided	 I-DOSAGE
daily	 I-DOSAGE
doses	 I-DOSAGE
on	 I-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
-	 I-DOSAGE
14	 I-DOSAGE
,	 O
and	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
(	 O
5.0	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
an	 O
intravenous	 O
infusion	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
15	 I-DOSAGE
of	 I-DOSAGE
each	 I-DOSAGE
4-week	 I-DOSAGE
cycle	 I-DOSAGE
.	 O

The	 O
[P1]	 O
FOLFIRI	 O
/	 O
B	 O
[P2]	 O
regimen	 O
comprised	 O
irinotecan	 O
(	 O
150	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
a	 O
90-min	 B-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
and	 O
l	 O
-	 O
leucovorin	 O
(	 O
200	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 B-DOSAGE
as	 I-DOSAGE
a	 I-DOSAGE
120-min	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
an	 O
intravenous	 O
bolus	 O
5-FU	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
a	 O
46-h	 B-DOSAGE
continuous	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
of	 O
5-FU	 O
(	 O
2,400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
and	 O
bevacizumab	 O
(	 O
5.0	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
an	 O
intravenous	 O
infusion	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
of	 I-DOSAGE
each	 I-DOSAGE
2-week	 I-DOSAGE
cycle	 I-DOSAGE
.	 O

The	 O
FOLFIRI	 O
/	 O
B	 O
regimen	 O
comprised	 O
[P1]	 O
irinotecan	 O
[P2]	 O
(	 O
150	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
a	 O
90-min	 B-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
and	 O
l	 O
-	 O
leucovorin	 O
(	 O
200	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 B-DOSAGE
as	 I-DOSAGE
a	 I-DOSAGE
120-min	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
an	 O
intravenous	 O
bolus	 O
5-FU	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
a	 O
46-h	 B-DOSAGE
continuous	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
of	 O
5-FU	 O
(	 O
2,400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
and	 O
bevacizumab	 O
(	 O
5.0	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
an	 O
intravenous	 O
infusion	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
of	 I-DOSAGE
each	 I-DOSAGE
2-week	 I-DOSAGE
cycle	 I-DOSAGE
.	 O

The	 O
FOLFIRI	 O
/	 O
B	 O
regimen	 O
comprised	 O
irinotecan	 O
(	 O
150	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
a	 O
90-min	 B-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
and	 O
[P1]	 O
l	 O
-	 O
leucovorin	 O
[P2]	 O
(	 O
200	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 B-DOSAGE
as	 I-DOSAGE
a	 I-DOSAGE
120-min	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
an	 O
intravenous	 O
bolus	 O
5-FU	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
a	 O
46-h	 B-DOSAGE
continuous	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
of	 O
5-FU	 O
(	 O
2,400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
and	 O
bevacizumab	 O
(	 O
5.0	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
an	 O
intravenous	 O
infusion	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
of	 I-DOSAGE
each	 I-DOSAGE
2-week	 I-DOSAGE
cycle	 I-DOSAGE
.	 O

The	 O
FOLFIRI	 O
/	 O
B	 O
regimen	 O
comprised	 O
irinotecan	 O
(	 O
150	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
a	 O
90-min	 B-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
and	 O
l	 O
-	 O
leucovorin	 O
(	 O
200	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 B-DOSAGE
as	 I-DOSAGE
a	 I-DOSAGE
120-min	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
an	 O
intravenous	 O
bolus	 O
[P1]	 O
5-FU	 O
[P2]	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
a	 O
46-h	 B-DOSAGE
continuous	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
of	 O
5-FU	 O
(	 O
2,400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
and	 O
bevacizumab	 O
(	 O
5.0	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
an	 O
intravenous	 O
infusion	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
of	 I-DOSAGE
each	 I-DOSAGE
2-week	 I-DOSAGE
cycle	 I-DOSAGE
.	 O

The	 O
FOLFIRI	 O
/	 O
B	 O
regimen	 O
comprised	 O
irinotecan	 O
(	 O
150	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
a	 O
90-min	 B-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
and	 O
l	 O
-	 O
leucovorin	 O
(	 O
200	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 B-DOSAGE
as	 I-DOSAGE
a	 I-DOSAGE
120-min	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
an	 O
intravenous	 O
bolus	 O
5-FU	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
a	 O
46-h	 B-DOSAGE
continuous	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
of	 O
[P1]	 O
5-FU	 O
[P2]	 O
(	 O
2,400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
and	 O
bevacizumab	 O
(	 O
5.0	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
an	 O
intravenous	 O
infusion	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
of	 I-DOSAGE
each	 I-DOSAGE
2-week	 I-DOSAGE
cycle	 I-DOSAGE
.	 O

The	 O
FOLFIRI	 O
/	 O
B	 O
regimen	 O
comprised	 O
irinotecan	 O
(	 O
150	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
a	 O
90-min	 B-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
and	 O
l	 O
-	 O
leucovorin	 O
(	 O
200	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
given	 B-DOSAGE
as	 I-DOSAGE
a	 I-DOSAGE
120-min	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
,	 O
an	 O
intravenous	 O
bolus	 O
5-FU	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
a	 O
46-h	 B-DOSAGE
continuous	 I-DOSAGE
intravenous	 I-DOSAGE
infusion	 I-DOSAGE
of	 O
5-FU	 O
(	 O
2,400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
)	 O
,	 O
and	 O
[P1]	 O
bevacizumab	 O
[P2]	 O
(	 O
5.0	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
kg	 I-DOSAGE
)	 O
,	 O
given	 O
as	 O
an	 O
intravenous	 O
infusion	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
of	 I-DOSAGE
each	 I-DOSAGE
2-week	 I-DOSAGE
cycle	 I-DOSAGE
.	 O

[P1]	 O
Bevacizumab	 O
[P2]	 O
was	 O
given	 O
to	 O
patients	 O
who	 O
had	 O
grade	 O
2	 O
or	 O
lower	 O
hypertension	 O
,	 O
proteinuria	 O
(	 O
protein	 O
≤1	 O
+	 O
or	 O
<	 O
2	 O
g	 O
of	 O
protein	 O
per	 O
24-h	 O
urine	 O
collection	 O
)	 O
,	 O
and	 O
grade	 O
1	 O
or	 O
lower	 O
bleeding	 O
,	 O
with	 O
no	 O
evidence	 O
of	 O
thrombosis	 O
or	 O
embolism	 O
.	 O